The Roche-backed oncology treatment developer floated below its range in an IPO in which Pfizer and Bristol-Myers Squibb both acquired shares.
CytomX, a US-based immuno-oncology company backed by pharmaceutical firm Roche, floated on Nasdaq yesterday with an $80m initial public offering yesterday.
The company issued 6.67 million shares priced at $12 each, below the $14 to $16 range it set last week. CytomX is the third corporate-backed biotechnology company, after Nabriva and Mirna Therapeutics, to float below its range in the past month.
Two more pharmaceutical companies, Pfizer and Bristol Myers-Squibb, bought a combined $15m of stock in…
